Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer
- PMID: 36946597
- DOI: 10.4088/JCP.22r14494
Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer
Abstract
Importance: "Psychotropic" drugs have widespread reach and impact throughout the brain and body. Thus, many of these drugs could be repurposed for non-psychiatric indications of high public health impact.
Observations: The selective serotonin reuptake inhibitor (SSRI) fluvoxamine was shown efficacious as a COVID-19 treatment based on randomized controlled trials (RCTs), and a benefit of other antidepressants has been posited based on observational and preclinical studies. In this review, we illuminate features of SSRIs and other psychiatric drugs that make them candidates to repurpose for non-psychiatric indications. We summarize research that led to fluvoxamine's use in COVID-19 and provide guidance on how to use it safely. We summarize studies suggestive of benefit of other antidepressants versus COVID-19 and long COVID. We also describe putative mechanisms of psychiatric drugs in treating long COVID, Alzheimer's disease, cancer, and other conditions.
Conclusion and Relevance: There is a potentially great clinical and public health impact of psychotropic drug repurposing. Challenges exist to such repurposing efforts, but solutions exist for researchers, regulators, and funders that overcome these challenges.
© Copyright 2023 Physicians Postgraduate Press, Inc.
Similar articles
-
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.J Clin Psychopharmacol. 2022 May-Jun 01;42(3):284-292. doi: 10.1097/JCP.0000000000001543. Epub 2022 Apr 14. J Clin Psychopharmacol. 2022. PMID: 35420565 Free PMC article. Review.
-
Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention.Pharmacopsychiatry. 2022 Jan;55(1):24-29. doi: 10.1055/a-1686-9620. Epub 2021 Dec 7. Pharmacopsychiatry. 2022. PMID: 34875696 Review.
-
Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis.Eur Neuropsychopharmacol. 2023 Jan;66:30-44. doi: 10.1016/j.euroneuro.2022.10.004. Epub 2022 Oct 20. Eur Neuropsychopharmacol. 2023. PMID: 36399837 Free PMC article.
-
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?J Clin Neurosci. 2021 Jun;88:163-172. doi: 10.1016/j.jocn.2021.03.010. Epub 2021 Mar 19. J Clin Neurosci. 2021. PMID: 33992179 Free PMC article. Review.
-
Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid.Assay Drug Dev Technol. 2021 Aug-Sep;19(6):373-385. doi: 10.1089/adt.2021.014. Epub 2021 Aug 10. Assay Drug Dev Technol. 2021. PMID: 34375133 Review.
Cited by
-
Anxiety and Alzheimer's disease pathogenesis: focus on 5-HT and CRF systems in 3xTg-AD and TgF344-AD animal models.Front Aging Neurosci. 2023 Nov 10;15:1251075. doi: 10.3389/fnagi.2023.1251075. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38076543 Free PMC article. Review.